Cem Onal1, Ozan Cem Guler2, Nese Torun3, Mehmet Reyhan3, Ali Fuat Yapar3. 1. Adana Dr. Turgut Noyan Research and Treatment Center, Department of Radiation Oncology, Başkent University Faculty of Medicine, 01120, Adana, Turkey. hcemonal@hotmail.com. 2. Adana Dr. Turgut Noyan Research and Treatment Center, Department of Radiation Oncology, Başkent University Faculty of Medicine, 01120, Adana, Turkey. 3. Adana Dr. Turgut Noyan Research and Treatment Center, Department of Nuclear Medicine, Başkent University Faculty of Medicine, Adana, Turkey.
Abstract
PURPOSE: To evaluate the effect of neoadjuvant androgen deprivation treatment (ADT) on prostate-specific membrane antigen (PSMA) tracer uptake demonstrated in 68Ga-PSMA-positron emission tomography (PET/CT) in non-metastatic hormone-naïve prostate cancer (PC) patients. MATERIALS AND METHODS: The clinical data of 108 PC patients who received neoadjuvant ADT were retrospectively analyzed. All patients had a baseline 68Ga-PSMA-PET/CT scan, and a second scan was delivered median of 2.9 months after the initiation of ADT. The maximum standardized uptake value (SUVmax) of primary tumor (SUVp) and metastatic lymph nodes (SUVln) as well as PSA response were assessed between pre- and post-ADT 68Ga-PSMA-PET/CT scans. RESULTS: There were significant decreases in posttreatment serum PSA, SUVp, and SUVln. A decrease in SUVp was seen in 91 patients (84%) with a median value of 66% (range, 5-100%), while 17 patients (16%) had no change in or an increase in PSMA tracer uptake with a median value of 24% (range, 0-198%). Patients with Gleason score (GS) of 7 had significantly higher metabolic response rates compared to other patients. The disease progression was significantly higher only in patients with GS > 7 disease compared to GS 7 disease. The PSA response to ADT was the lowest in patients with ISUP high-grade tumors. A total of 16 patients (15%) had progressive disease, and in 9 patients (8%), radiotherapy decisions were modified according to posttreatment 68Ga-PSMA-PET/CT scans. CONCLUSIONS: The current study includes the largest number of patients analyzed to date and demonstrates that ADT causes a significant decrease in serum PSA values and SUVp and SUVln. The authors demonstrate that 68Ga-PSMA-PET/CT may be used as a quantitative imaging modality after neoadjuvant ADT in hormone-naïve non-metastatic PC patients.
PURPOSE: To evaluate the effect of neoadjuvant androgen deprivation treatment (ADT) on prostate-specific membrane antigen (PSMA) tracer uptake demonstrated in 68Ga-PSMA-positron emission tomography (PET/CT) in non-metastatic hormone-naïve prostate cancer (PC) patients. MATERIALS AND METHODS: The clinical data of 108 PCpatients who received neoadjuvant ADT were retrospectively analyzed. All patients had a baseline 68Ga-PSMA-PET/CT scan, and a second scan was delivered median of 2.9 months after the initiation of ADT. The maximum standardized uptake value (SUVmax) of primary tumor (SUVp) and metastatic lymph nodes (SUVln) as well as PSA response were assessed between pre- and post-ADT 68Ga-PSMA-PET/CT scans. RESULTS: There were significant decreases in posttreatment serum PSA, SUVp, and SUVln. A decrease in SUVp was seen in 91 patients (84%) with a median value of 66% (range, 5-100%), while 17 patients (16%) had no change in or an increase in PSMA tracer uptake with a median value of 24% (range, 0-198%). Patients with Gleason score (GS) of 7 had significantly higher metabolic response rates compared to other patients. The disease progression was significantly higher only in patients with GS > 7 disease compared to GS 7 disease. The PSA response to ADT was the lowest in patients with ISUP high-grade tumors. A total of 16 patients (15%) had progressive disease, and in 9 patients (8%), radiotherapy decisions were modified according to posttreatment 68Ga-PSMA-PET/CT scans. CONCLUSIONS: The current study includes the largest number of patients analyzed to date and demonstrates that ADT causes a significant decrease in serum PSA values and SUVp and SUVln. The authors demonstrate that 68Ga-PSMA-PET/CT may be used as a quantitative imaging modality after neoadjuvant ADT in hormone-naïve non-metastatic PCpatients.
Authors: Sebastian Schmuck; Christoph A von Klot; Christoph Henkenberens; Jan M Sohns; Hans Christiansen; Hans-Jürgen Wester; Tobias L Ross; Frank M Bengel; Thorsten Derlin Journal: J Nucl Med Date: 2017-05-18 Impact factor: 10.057
Authors: Seung Chol Park; Joung Sik Rim; Han Yong Choi; Choung Soo Kim; Sung Joon Hong; Wun Jae Kim; Sang Eun Lee; Jae Mann Song; Jin Han Yoon Journal: Int J Urol Date: 2009-07-13 Impact factor: 3.369
Authors: Ali Afshar-Oromieh; Eleni Avtzi; Frederik L Giesel; Tim Holland-Letz; Heinz G Linhart; Matthias Eder; Michael Eisenhut; Silvan Boxler; Boris A Hadaschik; Clemens Kratochwil; Wilko Weichert; Klaus Kopka; Jürgen Debus; Uwe Haberkorn Journal: Eur J Nucl Med Mol Imaging Date: 2014-11-20 Impact factor: 9.236
Authors: Christos E Kyriakopoulos; Yu-Hui Chen; Michael A Carducci; Glenn Liu; David F Jarrard; Noah M Hahn; Daniel H Shevrin; Robert Dreicer; Maha Hussain; Mario Eisenberger; Manish Kohli; Elizabeth R Plimack; Nicholas J Vogelzang; Joel Picus; Matthew M Cooney; Jorge A Garcia; Robert S DiPaola; Christopher J Sweeney Journal: J Clin Oncol Date: 2018-01-31 Impact factor: 50.717
Authors: Ahmed Ebada Salem; Gabriel C Fine; Matthew F Covington; Bhasker R Koppula; Richard H Wiggins; John M Hoffman; Kathryn A Morton Journal: Cancers (Basel) Date: 2022-06-18 Impact factor: 6.575
Authors: Jyoti Roy; Margaret E White; Falguni Basuli; Ana Christina L Opina; Karen Wong; Morgan Riba; Anita T Ton; Xiang Zhang; Keith H Jansson; Elijah Edmondson; Donna Butcher; Frank I Lin; Peter L Choyke; Kathleen Kelly; Elaine M Jagoda Journal: Mol Imaging Biol Date: 2021-04-23 Impact factor: 3.488
Authors: Stefano Fanti; Karolien Goffin; Boris A Hadaschik; Ken Herrmann; Tobias Maurer; Steven MacLennan; Daniela E Oprea-Lager; Wim Jg Oyen; Olivier Rouvière; Nicolas Mottet; Anders Bjartell Journal: Eur J Nucl Med Mol Imaging Date: 2020-07-02 Impact factor: 9.236
Authors: Samuel J Galgano; Andrew M McDonald; Soroush Rais-Bahrami; Kristin K Porter; Gagandeep Choudhary; Constantine Burgan; Pradeep Bhambhvani; Jeffrey W Nix; Desiree E Morgan; Yufeng Li; John V Thomas; Jonathan McConathy Journal: AJR Am J Roentgenol Date: 2020-10-14 Impact factor: 6.582